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PURPOSE. The purpose of this study was to evaluate the role of inflammatory/lipid markers and
potential risk factors for diabetic retinopathy (DR) development in newly diagnosed patients
with type 2 diabetes mellitus (T2DM).
METHODS. Participants in this study were 1062 patients with newly diagnosed T2DM.
Demographic and clinical data of patients were collected. Assessment of DR status was
performed using digital two-field photography. In addition, HbA1c (%), lipid profile, and
urinary albumin were measured at recruitment. The following inflammatory markers were
also measured: serum C-reactive protein, white blood cells, platelet, adiponectin, IL-4, IL-6, IL-
10, vascular endothelial growth factor, tumor necrosis factor-a (TNF-a), IL-1b, IL-1 receptor
antagonist (IL-1RA), and monocyte chemotactic protein-1. Univariate and multivariate
analyses of the association of various potential risk factors and DR were conducted.
RESULTS. Univariate analysis showed that male sex, any cardiovascular event, and HbA1c were
positively associated with DR, while IL-1RA, IL-1b, IL-6, and TNF-a were significantly
negatively associated with presence of DR in the cohort. Risk factors that remained
significantly associated with DR presence at the multivariate analysis were male sex, any
cardiovascular event, HbA1c, and IL-1RA.
CONCLUSIONS. Our study demonstrated that HbA1c levels, male sex, and previous cardiovascular
events were risk factors for presence of DR in people with newly diagnosed T2DM, while IL-
1RA seemed to have a protective role. The prevalence of DR in our population was 20.2%,
reflecting current practice. Our findings may contribute to future risk-based modelling of
screening for DR.
Keywords: diabetes, inflammatory, lipid, biomarkers, model, risk factors
Diabetes mellitus (DM) affects over 400 million peopleworldwide and it is expected to affect 642 million by
2040.1 Diabetic retinopathy (DR) is one of the most common
complications of DM and is the leading cause of blindness
among adults under 45 years old in the industrialized world.1–3
Early stages of DR (nonproliferative DR) are characterized by
microaneurysms, dot and blot hemorrhages, and exudates,
while in the later stages retinal neovascularization and its
complications (proliferative DR) are evident.4,5 Diabetic mac-
ular edema (DME) may occur at any stage of DR and is caused
by increased vascular permeability and resultant leakage of
proteins and lipid exudation in the macula.4,5 The United
Kingdom Prospective Diabetes Study (UKPDS) reported 20
years before that 30% of participants had microvascular
complications at diagnosis.6 However, this observation may
not be applicable in patients with type 2 DM (T2DM) today
because of early diagnosis and better management of DM, as
well as robust screening of DR in primary care. It is worth
mentioning that studies examining prevalence of DR in people
with new-onset DM are scanty.7–9
The pathogenesis of DR is multifactorial, but increasing
evidence points to the involvement of inflammation in DR
pathophysiology.10–20 Specifically, previous studies have shown
that low-grade subclinical inflammation can damage retinal
vasculature, leading to neovascularization or macular edema,
and pro- and anti-inflammatory markers in the serum and ocular
fluids have been shown to be related to DR.10–20 The role of
dyslipidemia in the pathogenesis of DR is poorly understood.
Studies on various lipid markers, such as serum total
cholesterol, triglycerides, low density lipoproteins (LDLs), and
high density lipoproteins (HDLs) in DR have reported
conflicting results.21,22
Apart from inflammation and dyslipidemia, several other risk
factors have been described in DR. In a recent meta-analysis,
diabetes duration and ethnicity have been substantiated as
nonmodifiable risk factors and raised HbA1c and blood pressure
as risk factors that are amendable to modification.1 Neverthe-
less, a recently published Cochrane Systematic Review
reported that there is lack of evidence to support that control
of hypertension leads to prevention of DR progression.23
Obesity, smoking, pregnancy, genetic factors, and diabetic
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kidney disease have been previously evaluated as potential risk
factors for DR, but these associations remain controver-
sial.2,24–27
One study reported DR and macrovascular complications
each in one-third of people with T2DM of mean duration of 9
years.28 Another described 20% to 30% microvascular and 40%
macrovascular complications in patients with mean duration of
4 years.29 However, it is important to understand the profile of
patients with DR in newly diagnosed T2DM, especially in
countries where there is robust DR screening because it will
enable us to identify patients at risk of DR progression earlier
in the course of their disease. The purpose of this study was to
evaluate the role of inflammatory/lipid markers and potential
risk factors for DR development in newly diagnosed patients
with T2DM.
METHODS
Design
This is a population-based, cross-sectional study based on the
baseline data from participants of the South London-Diabetes
(SOUL-D) study. SOUL-D is a prospective cohort of people newly
diagnosed with T2DM, aiming to investigate the role of various
biopsychosocial factors on biomedical outcomes over a period
of 2 years.30 Ethical approval was granted by the King’s College
Hospital Research Ethics Committee (reference 08/H0808/1)
and by Lambeth, Southwark, and Lewisham Primary Care Trusts
(reference RDLSLB 410). The study was conducted according to
the tenets of the Declaration of Helsinki and written informed
consent was obtained from all the participants.
Setting and Sampling Frame
Three adjacent inner-city boroughs (Lambeth, Southwark, and
Lewisham) in South London, which serve a multiethnic and
socioeconomically diverse population of approximately 0.75
million UK residents, participated in the study. The sampling
frame included 96 of the 138 general practices (primary care
clinics in the UK’s Government-funded National Health
Service) in these boroughs.30 Every 6 months, each practice’s
diabetes register was searched to identify patients with a new
diagnosis of T2DM.
Inclusion-Exclusion Criteria
T2DM was diagnosed according to World Health Organization
(WHO) guidelines31 and the diagnosis validated at recruitment
by patient’s history and review of the medical records. The
inclusion criteria were: age 18 to 75 years at diagnosis and
diagnosis of T2DM not more than 6 months before recruitment
to the study. The exclusion criteria were: DM other than T2DM
(such as gestational diabetes); patient not fluent in English;
known severe mental illness; a separate advanced or terminal
condition; and severe advanced diabetic complications defined
as being registered blind, requiring dialysis, or having had an
above-the-knee amputation. Recruitment was conducted be-
tween May 2008 and September 2012. In this study, we have
only included patients with full data set including serum
markers.
Measurements
The following data were recorded and coded: age (years), sex,
employment status, legal partnership status, self-reported
ethnicity based on 2001 UK Census methods.32 Height, weight,
body mass index (kg/m2), and systolic and diastolic blood
pressure (mm Hg) at diagnosis were taken from the medical
record and measured by the study team at recruitment, with
systolic blood pressure (SBP) and diastolic blood pressure
(DBP) taken after 15 minutes of rest in the sitting position by
using a mercury sphygmomanometer.
History of macrovascular disease (myocardial infarction
[MI], coronary artery bypass graft [CABG], cerebrovascular
accident [CVA], carotid or limb revascularization, and ampu-
tation) or microvascular one (erectile dysfunction), smoking
status, as well as current prescribed medications including
diabetes tablets, insulin, cholesterol lowering agents, antihy-
pertensives, diuretics, and medications with a possible anti-
inflammatory action (statins, fibrates, systemic steroids,
nonsteroidal anti-inflammatory drugs, and COX-2 inhibitors)
were also recorded. They were assessed by self-report and
validated by medical records review. If there were several
macrovascular complications, the date of the first presentation
of each complication was recorded.
Retinopathy was assessed from the patient’s first retinal eye
screen. For all patients, this was performed by the local
Diabetes Eye Complication Screening (DECS) service, using
digital two-field photography, according to national guide-
lines.33 Images were coded by trained graders, using the
English Retinopathy Minimum grading system.34 Retinopathy
was coded as any retinopathy present or absent in at least one
eye. The worst eye defined the level of retinopathy. Moreover,
history of previous laser photocoagulation or presence of
cataract were recorded.
Additionally, HbA1c (%), lipid profile (mM), and urinary
albumin were measured at recruitment. The laboratory tests
were analyzed at the one of the three accredited laboratories
used by the participants’ general practice: HbA1c using affinity
chromatography in the Primus Ultra 2 analyzer (Primus
Corporation, Kansas City, MO, USA); lipid profile using Siemens
Advia 2400 analyzer; and glucose using hexokinase, plasma
measurement (Siemens Diagnostics, Frimley, UK). The detec-
tion limits of the assays were as follows: triglyceride (T) 0.01
mM, total cholesterol 0.01 mM, and HDL cholesterol 0.01 mM;
LDL cholesterol was calculated using the Friedewald formula.
Urinary albumin to creatinine ratio (ACR) was measured at
diagnosis using Siemens Advia 2400, the polyethylene glycol-
enhanced immunoturbidimetric assay for urinary albumin, and
the Jaffe reaction for urinary creatinine. Participants were
considered positive for microalbuminuria for ratios ‡3 and
negative for ratios <3. Single random assessment of ACR is the
norm for excluding microalbuminuria during annual review in
primary care owing to the convenience of acquiring the
sample.35
The following inflammatory markers were also measured:
serum C-reactive protein (CRP) by a high-sensitivity CRP (hs-
CRP) using an Advia 2400 analyzer, with an assay detection
limit of 0.1 mg/L; white blood cells (WBCs) and platelet (PLT)
using an Advia 2100 analyzer and adiponectin using ELISA kits
(R&D Systems Europe, Oxon, UK), with a detection limit of
0.246 mg/L. IL-4, IL-6, IL-10, vascular endothelial growth factor
(VEGF), tumor necrosis factor-a (TNF-a), IL-1b, IL-1 receptor
antagonist (IL-1RA), and monocyte chemotactic protein-1
(MCP-1) were all measured from serum samples centrifuged
from venous blood samples taken after an overnight fast and
stored between 40 and 808C using cytokine-array biochip
kits (Randox, Belfast, UK) and analyzed using the Randox
Evidence Investigator. The inter- and intraassay coefficients of
variation for all analytes measured using these kits are <15%
and <10%, respectively.
Statistical Analysis
The main characteristics of the cohort are presented as mean
6 standard deviation or as proportion (percentage) of patients.
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Univariate and multivariate analyses of the association of
various potential risk factors and DR were conducted. Subjects
with missing values for the outcome variables (presence or
absence of DR) were excluded from the analysis. At the
univariate analysis, ordinal logistic regression was performed;
the dependent variable was converted to an ordinal variable
with four levels (1: minimum value-25th percentile; 2: 25th
percentile-median; 3: median-75th percentile; and 4: 75th
percentile-maximum value), where applicable. Nevertheless,
when the median was equal to the maximum value of the
variable due to markedly skewed distribution, as well as to the
presence of numerous ties, the ordinal logistic regression
model was obligatorily degenerated to logistic regression
model (0: values below median; 1: values equal to median-
maximum value). The odds ratios (ORs) with the respective
95% confidence intervals (CIs) are indicated in the text. At the
multivariate analysis, only factors proven significant (P < 0.05)
at the univariate analysis were tested in the stepwise
multivariate model as independent variables; in the final
model, only the statistically significant variables were retained
(i.e., backward-selection statistical procedure). Statistical anal-
ysis was performed using STATA/SE 13 statistical software
(Stata Corporation, College Station, TX, USA). A P value <0.05
was considered as statistically significant.
RESULTS
Table 1 shows the demographic and clinical characteristics, as
well as the laboratory findings of our study sample, comprising
of 1062 patients with newly diagnosed T2DM. Their mean age
was 56.0 6 10.9 years. 55.1% were male. As far as ethnicity is
concerned, 53.2%, 33.9%, 6.6%, and 6.3% were white, black,
Asian, or mixed, respectively. The mean HbA1c at recruitment
was 6.9% (52 mmol/mol), with 76.6% of patients having HbA1c
‡7.5%. Regarding complications of DM, 8.9% of patients
reported any cardiovascular event (macrovascular complica-
tions), 15.1% had microalbuminuria, 56.8% of male patients
reported erectile dysfunction), and 20.2% of patients had any
severity grade of DR (microvascular complications).
Table 2 shows the results of the univariate analysis. Male sex
(OR¼ 1.58; 95% CI¼ 1.16–2.14, P¼ 0.004), any cardiovascular
event (OR¼ 1.65; 95% CI¼ 1.03–2.65, P¼ 0.039), and HbA1c
(OR ¼ 1.62; 95% CI ¼ 1.16–2.25, P ¼ 0.005) were positively
TABLE 1. Demographic and Clinical Characteristics, as well as
Laboratory Results of Our Study Sample
N (%)
Age, mean 6 SD, y 56.0 6 10.9
Sex
Male 585 (55.1)
Female 477 (44.9)
Race
White 565 (53.2)
Black 360 (33.9)
Asian 70 (6.6)
Mixed 67 (6.3)
Legal partnership
Married 569 (53.6)
Single/divorced/widowed 493 (46.4)
Current employment
Yes 527 (49.6)
No 535 (50.4)
Smoking
Current 208 (19.6)
Former 466 (43.9)
Never 388 (36.5)
Duration of diabetes
<6 mo 720 (67.8)
‡6 mo 342 (32.2)
HbA1c (%)
<7.5 249 (23.4)
‡7.5 813 (76.6)
Cataract
Yes 105 (9.9)
No 957 (90.1)
Body mass index
<25 744 (70.1)
‡25 318 (29.9)
Central obesity
Yes 940 (88.5)
No 122 (11.5)
Hypertension
Yes 506 (47.7)
No 556 (52.4)
Medications, yes
Tablets 582 (54.8)
Insulin 34 (3.2)
Statins/fibrates 644 (60.6)
Antihypertensives 566 (53.3)
Any cardiovascular event
Yes 95 (8.9)
No 967 (91.1)
DR
Yes 214 (20.2)
No 848 (79.8)
Erectile dysfunction*
Yes 332 (56.8)
No 253 (43.2)
Microalbuminuria
Positive 160 (15.1)
Negative 902 (84.9)
TABLE 1. Continued
Mean 6 SD
HbA1c, % 6.96 6 1.38
Creatinine, lM 81.5 6 25.6
CRP, mg/L 5.04 6 7.69
IL-1ra, pg/mL 526.7 6 342.2
IL-1b, pg/mL 2.23 6 3.99
IL-4, pg/mL 1.50 6 0.90
IL-6, pg/mL 8.74 6 27.88
IL-10, pg/mL 0.63 6 0.87
VEGF, pg/mL 90.9 6 66.7
Adiponectin, ng/mL 6067.3 6 3982.0
TNF-a, pg/mL 2.41 6 5.09
MCP-1, pg/mL 111.7 6 63.5
Cholesterol, mM 4.59 6 1.05
LDL, mM 2.66 6 0.88
HDL, mM 1.21 6 0.34
Triglycerides, mM 1.67 6 1.11
WBC, 3106 6.82 6 2.03
PLT, 3103 269.9 6 76.9
* The percentage was based only on male patients.
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associated with DR. IL-1RA (OR¼0.84; 95% CI¼0.73–0.96, P¼
0.009), IL-1b (OR¼ 0.86; 95% CI¼ 0.75–0.98, P¼ 0.023), IL-6
(OR¼ 0.80; 95% CI¼ 0.70–0.92, P¼ 0.001), and TNF-a (OR¼
0.84; 95% CI ¼ 0.73–0.96, P ¼ 0.009) were significantly
negatively associated with presence of DR in the cohort.
Table 3 shows the results of the multivariate analysis. Risk
factors that remained associated significantly with DR presence
were male sex (OR¼ 1.44; 95% CI¼ 1.05–1.99, P¼ 0.024), any
cardiovascular event (OR ¼ 1.77; 95% CI ¼ 1.09–2.88, P ¼
0.022), HbA1c (OR¼ 1.60; 95% CI¼ 1.13–2.25, P¼ 0.007), and
IL-1RA (OR¼0.81; 95% CI¼0.71–0.93, P¼0.004), while IL-1b,
IL-6, and TNF-a lost their significance.
DISCUSSION
In our study of people with newly diagnosed T2DM, recruited
between 2008 and 2012, DR remains a significant microvascu-
lar complication, with a prevalence of 20.2%. Presence of DR
was significantly associated with male sex, HbA1c levels, and
any previous cardiovascular event, while IL-1RA levels were
found to be protective, surviving multivariate analysis.
TABLE 2. Results of the Univariate Analysis Regarding Factors Potentially Associated With DR Presence
Variable Category or Increment OR (95% CI) P Value
Age One quartile increase 0.99 (0.87–1.13) 0.873
Sex Male vs. female 1.58 (1.16–2.14) 0.004
Race Black vs. white 1.11 (0.80–1.53) 0.542
Asian vs. white 1.00 (0.54–1.86) >0.999
Mixed vs. white 1.25 (0.69–2.28) 0.457
Legal partnership Single/widowed/divorced vs. married/cohabiting 0.96 (0.72–1.30) 0.809
Current employment Yes vs. no 0.84 (0.62–1.13) 0.247
Smoking Current vs. never 0.99 (0.66–1.49) 0.978
Former vs. never 0.77 (0.54–1.06) 0.106
DM duration ‡6 mo vs. <6 mo 1.13 (0.83–1.55) 0.441
Cataract Yes vs. no 0.90 (0.54–1.50) 0.675
Any cardiovascular event Yes vs. no 1.65 (1.03–2.65) 0.039
Any microvascular* Yes vs. no 1.26 (0.70–2.27) 0.432
Erectile dysfunction* Yes vs. no 1.26 (0.83–1.91) 0.274
Body mass index ‡25 vs. <25 0.95 (0.69–1.32) 0.767
Central obesity Yes vs. no 1.02 (0.64–1.62) 0.945
Hypertension Yes vs. no 1.04 (0.77–1.40) 0.817
Medications
Antidiabetic tablets Yes vs. no 1.20 (0.89–1.63) 0.226
Insulin Yes vs. no 0.82 (0.33–2.00) 0.657
Statins/fibrates Yes vs. no 1.29 (0.95–1.76) 0.108
Antihypertensives Yes vs. no 0.92 (0.68–1.24) 0.578
HbA1c, % ‡7.5 vs. <7.5 1.62 (1.16–2.25) 0.005
Triglycerides, mM ‡2.0 vs. <2.0 0.95 (0.67–1.33) 0.751
Total cholesterol, mM ‡5.0 vs. <5.0 1.11 (0.81–1.52) 0.525
HDL, mM ‡1.2 vs. <1.2 0.86 (0.63–1.17) 0.333
LDL, mM ‡3.0 vs. <3.0 1.10 (0.79–1.53) 0.577
WBC, 3106 ‡11 vs. <11 1.05 (0.48–2.34) 0.896
PLT, 3103 ‡450 vs. normal 0.76 (0.26–2.24) 0.614
150 vs. normal 0.99 (0.40–2.46) 0.977
Creatinine, lM ‡120 vs. <120 1.37 (0.53–3.51) 0.516
Microalbuminuria Positive vs. negative 1.56 (0.78–2.73) 0.129
CRP, mg/L ‡5.0 vs. <5.0 0.80 (0.58–1.11) 0.188
IL-1ra, pg/mL One quartile increase 0.84 (0.73–0.96) 0.009
IL-1b, pg/mL One quartile increase 0.86 (0.75–0.98) 0.023
IL-4, pg/mL One quartile increase 0.91 (0.79–1.03) 0.124
IL-6, pg/mL One quartile increase 0.80 (0.70–0.92) 0.001
IL-10, pg/mL One quartile increase 0.91 (0.79–1.04) 0.145
VEGF, pg/mL One quartile increase 1.01 (0.89–1.15) 0.866
Adiponectin, ng/mL One quartile increase 0.92 (0.80–1.05) 0.209
TNF-a, pg/mL One quartile increase 0.84 (0.73–0.96) 0.009
MCP-1, pg/mL One quartile increase 1.00 (0.87–1.14) 0.946
Bold values denote statistical significance.
* The OR was derived based only on male patients.
TABLE 3. Results of the Multivariate Analysis, Showing Factors
Significantly Associated With DR Presence
Variable
Category or
Increment OR (95% CI) P Value
Sex Male vs. female 1.44 (1.05–1.99) 0.024
Any cardiovascular
event
Yes vs. no 1.77 (1.09–2.88) 0.022
HbA1c, % ‡7.5 vs. <7.5 1.60 (1.13–2.25) 0.007
IL-1RA, pg/mL One quartile
increase
0.81 (0.71–0.93) 0.004
Bold values denote statistical significance.
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Therefore, these four variables should be incorporated into any
risk-based model for screening of DR.
The SOUL-D patients have a lower incidence of retinopathy
compared to UKPDS patients (20.2% vs. 36%).26 The observed
differences in complication status between SOUL-D and
UKPDS reflect a change in the risk of microvascular disease
prevalence, probably driven by earlier diagnosis from screen-
ing for diabetes and better management of all long-term
conditions, including hypertension and hyperlipidemia in
primary care in the UK.30 This is in line with a recent
population-based study, in which the prevalence of DR in
screening-detected patients with T2DM was estimated to be
13%.36 The SOUL-D patients were identified by a variety of
pathways, including screening.
The pathogenesis of DR is multifactorial and identification
of the major risk factors for DR presence remains challenging.
Previous studies have found that the duration of DM was a
strong risk factor for the development of DR. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy reported the
prevalence of any retinopathy to be 8% in patients with 3 years
of DM, 25% at duration of 5 years, 60% at duration of 10 years,
and 80% at duration of 15 years.37 The incidence of DR in our
study was relatively high, given that only newly diagnosed
patients were included. This could be possibly explained by
the hospital-based sample in our study. In addition, since South
East London has highly mobile and migrant population, late
diagnosis of diabetes in this population may explain the higher
incidence of DR in our study cohort. Prediagnosis duration of
diabetes is of course unknown, but another contributing factor
may be that the patients included in this study are of
multiethnic origin. We have reported previously that DR is
more prevalent and severe in people with T2DM with Black
and South Asian origin.38 In addition, the advances in better
retinal imaging systems may explain the higher detection rate
of DR in our cohort.
Diabetes control, as reflected by the level of HbA1c, has
been previously reported as an independent factor for the
incidence of DR. In one study, 1% reduction in HbA1c leads to a
35% reduction in microvascular complications of DM.39 Overall
glycemic control, as expressed by HbA1c, and/or glycemic
variability are important associations of DR development.40
Therefore, HbA1c should be definitely included in any risk-
based model for DR screening.
Male sex was also found to be associated with the presence
of DR. Similar observations were made by Pradeepa et al.41 and
in the Los Angeles Latino Eye Study42 and may be related to life
style differences, other comorbidities, or genetic implication.
Furthermore, local neuroretinal function in T2DM, which can
be used to predict retinopathy, has been reported to be more
abnormal in adult males compared with adult females.43 It is
also interesting to note that all these studies included patients
of Black and South Asian origin.41,42
Our study found an association with previous cardiovascu-
lar events and presence of DR. In fact, the strength of relation
between DR and macrovascular complications, such as
cardiovascular disease in this study, is as strong as in
nephropathy.44 An 8-year cohort study found that patients
who had mild DR were already at higher risk of coronary heart
disease or stroke, in accordance with the Chennai Urban Rural
Epidemiology Study.45,46 In contrast, although previous macro-
vascular complications were predictive factors for presence of
DR in newly diagnosed patients with T2DM, our study did not
show any association between the presence of microalbumin-
uria and DR. This interesting finding in this study suggests that
the link between retinopathy and macrovascular complications
may be better explained by shared risk factors of obesity,
hyperlipidemia, and blood pressure. In contrast, an inflamma-
tory link may better explain the association of microalbumin-
uria and retinopathy as studies have shown that
microalbuminuria may not manifest itself initially and may
precede the onset of sight threatening complications.47,48
It is also worthy to note that the majority of inflammatory
and lipid markers, except for IL-1RA, were found not to be
predictive risk factors for the detection of DR at early stages.
This could be explained by the fact that our study sample
included only patients with newly diagnosed DM with mild
retinopathy, where potentially events related to chronicity had
not set in. Studies investigating inflammatory markers to date
have shown an association of proinflammatory cytokines with
sight threatening retinopathy.19,49 IL-1RA is an early inhibitory
cytokine, which suppresses proinflammatory cytokines and T
lymphocyte responses. It is plausible that a decrease in IL-1ra is
an early sign in DR.50 Lacraz et al.51 have shown the beneficial
effect of IL-1Ra on islet endothelial/immune cells and fibrosis
parameters in diabetic rats. Therefore, longer term follow-up is
needed to establish the predictive value of this marker on sight
threatening retinopathy, as well as the potential therapeutic
effect of IL-1RA in patients with DR.
Limitations of this study were that people who were
housebound and not able to visit the general practitioner were
excluded. The strengths of the study were the high participa-
tion rate and the comprehensiveness of the setting.
In conclusion, our study demonstrated that HbA1c levels,
male sex, and previous cardiovascular events were risk factors
for presence of DR in people with newly diagnosed T2DM,
while IL-1RA seemed to have a protective role. The prevalence
of DR in our population was 20.2%, reflecting current practice.
Our findings may contribute to future risk-based modelling of
screening for DR.
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